Table 1: Effect of Escitalopram on mitochondrial respiratory chain enzymes.
| Groups | Complex-I (μmole NADH oxidized/min/mg protein) | Complex-II (μmole SDH oxidized/min/mg protein) | Complex-IV (μmole cytochrome oxidized/min/mg protein) | MTT reduction (% of control) |
|---|---|---|---|---|
| Values are expressed as mean ± standard deviation (SD); n = 6. | ||||
| Significance was determined using one way ANOVA followed by Tukey’s test. | ||||
| #Significantly different from control group (p<0.05). | ||||
| *Significantly different from 3-NP treated group (p<0.05). | ||||
| **Significantly different from E-10 + 3-NP-treated group (p<0.05). | ||||
| SD- standard deviation; ANOVA - analysis of variance. | ||||
| Control | 9.33 ± 0.34 | 93.06 ± 8.00 | 7.70 ± 0.95 | 100 ± 0.029 |
| 3-NP | 4.40 ± 0.34# | 26.57 ± 2.03# | 3.06 ± 0.25# | 35.77 ± 0.073# |
| E-10 + 3NP | 6.37 ± 0.23* | 50.70 ± 3.24* | 4.35 ± 0.21* | 58.33 ± 0.937* |
| E-20 + 3NP | 7.63 ± 0.40*,** | 73.51 ± 2.45*,** | 6.05 ± 0.37*,** | 73.24 ± 1.327*,** |
| E-20 | 9.74 ± 0.66 | 88.48 ± 5.35 | 8.44 ± 0.82 | 89.01 ± 2.91 |